Clinical Trial

The Effectiveness of Transdiagnostic CBT Protocol on Anxiety Disorders

Recruiting
View on ClinicalTrials.gov →
Summary
The transdiagnostic approach argues that the common features are needed to be taken into account \[e.g. distress intolerance (DI), intolerance of uncertainty (IU), worry)\] underlying emotional disorders rather than evaluating them separately due to the fact that the dissection of anxiety disorders has increased with each emerging version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), in which the classification of anxiety disorders resulted in an increased number of intervention protocols for each disorder. This also caused an increase of comorbidity among anxiety disorders. Transdiagnostic approach offers a unified protocol (UP) for strengthening the common features, and thereby both preventing the emergence of emotional disorders or intervening the symptom severity of emotional disorders, which can be applied to different types of emotional disorders. The main aim of this study is to develop a UP which is planned to be applied as a group therapy. The UP will include interventions developing the levels of common transdiagnostic features (DI, IU and worry). The study's second aim is to investigate the effect of the developed UP on DI, IU and worry. The third one is to search the effect of the developed UP on symptom severity levels of anxiety disorders. Fourthly, this study will search if the levels of transdiagnostic common features (DI, IU and worry) will predict the levels of symptom severity of anxiety disorders'.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-20.
Status change: Not Yet Recruiting → Recruiting 2024-09-03
Trial Details
NCT Number NCT06422728
Lead Sponsor Ibn Haldun University
Conditions Anxiety Disorders, Social Anxiety Disorder, Generalized Anxiety Disorder, Panic Disorder, Anxiety Disorder NOS
Enrollment 60 participants
Start Date 2024-06-20
Primary Completion 2024-09 (estimated)
Study Completion 2025-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19